BeStock  
Markets › Compare › RARE vs REPL

RARE vs REPL

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
RARE · Ultragenyx Pharmaceutical$16.48 ▼ 4.30%
REPL · Replimune$19.07 ▼ 0.83%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

469133197262Nov 24, '25May 26, '26Nov 20, '26
  • RARE -49.7%
  • REPL +103.1%

Head to head

MetricRAREREPL
Price$16.48$19.07
Change today▼ 4.30%▼ 0.83%
Market cap$1.68B$1.81B
Return, 3 months-35.9%+29.6%
Return, year to date-28.3%+96.2%
Return, 1 year-50.9%+107.3%
P/E (TTM)––
P/B-4.58.8
P/E percentile vs own 5y96th17th
Dividend yield––
Revenue growth (YoY, latest qtr)+8.1%–
Net profit growth (YoY)+34.4%+31.3%
Gross margin82.9%–
Operating margin-64.0%–
Net margin-71.8%–
Return on equity–-115.8%
Analyst target vs. price+54.1%+25.9%
Analyst buy share47%100%
RSI (14)5154
30-day volatility58.7%99.2%
Max drawdown, 1 year-64.8%-84.2%
Trend readLeaning bearishLeaning bullish
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • REPL is the largest of the group by market value.
  • REPL has returned the most over the past year.
  • RARE has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top